AUSTIN, Texas--(BUSINESS WIRE)--Aeglea BioTherapeutics, Inc., a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the promotion of Charles N. York to chief financial officer from vice president of finance and accounting. Mr. York has been with the company since its inception in 2013, serving first as a consultant before joining as a full-time employee in the summer of 2014. He has 16 years of financial expertise that includes acquisitions and divestitures, private equity transactions, and an initial public offering.
Help employers find you! Check out all the jobs and post your resume.
